media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Vaccination should be expanded from children to the entire life cycle population

In 2021, the influenza vaccination rate among adults aged 18-59 in China was only 0.52%, and the vaccination rates for pneumonia and influenza among chronic patients such as chronic obstructive pulmonary disease are also worrying. “On December 5th, Liang Wannian, a professor at Tsinghua University and dean of the School of General Medicine at Southern University of Science and Technology, stated at the adult vaccine consensus conference and special seminar that challenges such as insufficient accessibility and convenience of vaccination services, high costs, and vaccine hesitancy continue to increase the risk of illness among adults, exacerbating the burden on families, society, and medical service systems. “China has made remarkable achievements in children’s immunization planning, but adult immunization faces weaknesses.” Yin Zundong, a researcher at the Immunization Planning Center of the China Center for Disease Control and Prevention, said that in the context of population aging, infectious diseases such as ...
- Source: drugdu
- 46
- December 9, 2025
TEBAO Biotech’s Yipeisheng is included in medical insurance to realize clinical value through differentiated innovation

On December 7th, according to Zhongzheng News and Zhongzheng Network (Wang Luo), the long-acting growth hormone – Yipei Growth Hormone Injection (trade name: Yipei Sheng) independently developed by Tebao Biotechnology ®） Successfully included in the medical insurance catalog through negotiation. This entry into medical insurance has profound significance for TeBao Biotechnology. It not only marks the product’s qualification for national market access, but also verifies a core business proposition in the context of medical insurance negotiations: differentiated innovative drugs with significant clinical advantages and higher safety can only gain recognition and support. Yi Peisheng ® The smooth entry into the market is due to its solid “quality hard power”, especially its breakthrough innovation and safety upgrade in molecular design, which has built a differentiation advantage that is difficult to replicate for the product. In the field of pediatric medication, the ability to achieve higher “safety” through technological means is ...
- Source: drugdu
- 51
- December 9, 2025
CPhI North America

Organiser：Informa Markets Time： June 2nd – 4th, 2026 Address：1101 Arch Street Philadelphia, PA 19107, Philadelphia, PA, United States Exhibition hall：Pennsylvania Convention Center, Philadelphia Product range: Active Pharmaceutical Ingredients (API): Vitamins, hormones, sulfonamides, antipyretic analgesics, tetracyclines, amino acids and their derivatives, chloramphenicols, digestive system medications, other anti-infective agents, penicillins, aminoglycosides, lincomycins, cardiovascular system medications, anti-parasitic drugs, cephalosporins, macrolides, respiratory system medications, central nervous system medications, and other Western pharmaceutical ingredients. Packaging Equipment: Pharmaceutical machinery, packaging machinery, packaging materials, pharmaceutical production equipment and technology, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, sterilization and dispensing systems, and laboratory instrumentation. Pharmaceutical Products: Various traditional Chinese patent medicines, Western medicines, new drugs, various APIs, chemical pharmaceuticals, pharmaceutical intermediates, biopharmaceuticals, traditional medicines, Chinese herbal medicines, herbal extracts, animal and plant extracts, veterinary drugs, food ingredients and additives, etc. About CPhI North America： CPhI North America, the United States World Pharmaceutical Ingredients Exhibition, is ...
- Source: drugdu
- 48
- December 9, 2025
Conbercept ophthalmic injection included in medical insurance catalog

December 8th, Yasuhiro Pharmaceuticals(002773) issued an announcement stating that Conbercept ophthalmic injection has been included in the “National Basic Medical Insurance” .The drug is listed as a Category B drug in the ” National Respiratory Health Insurance and Work Injury Insurance Drug Catalog (2025)”. This decision, issued by the National Healthcare Security Administration on December 7, 2025, signifies official recognition of the drug’s importance in the treatment of retinal diseases. Conbercept ophthalmic injection is currently the only domestically produced innovative drug in the catalog that covers all four major indications for fundus diseases.The company stated that inclusion in the national medical insurance catalog will improve the stability and accessibility of medication for patients. Simultaneously, the company is actively conducting Phase III clinical trials of its high-dose version of Conbercept, as well as clinical trials of gene therapy drugs KH631 and KH658 in both China and the United States. The new ...
- Source: drugdu
- 55
- December 8, 2025
Dongcheng Pharmaceuticals Receives Approval for Clinical Trial of 177Lu-LNC1009

On December 7th, Dongcheng Pharmaceutical(002675) issued an announcement stating that its holding subsidiary, Lannacheng, received the drug clinical trial approval notice for 177Lu-LNC1009 injection issued by the National Medical Products Administration on December 5, 2025, and plans to conduct relevant clinical trials in the near future. This drug is a dual-target radiotherapy drug, mainly used for the treatment of patients with FAP-positive and integrin αvβ3-positive advanced malignant solid tumors. The total investment in the research and development of 177Lu-LNC1009 injection is approximately RMB 13.58 million. Currently, there are no similar products on the market domestically or internationally, and no relevant sales data is available. The company emphasizes that the process from drug development to market launch is lengthy and involves uncertainties, reminding investors to be aware of the risks. In the first three quarters of 2025, Dongcheng Pharmaceutical achieved revenue of 2.043 billion yuan and net profit attributable to the ...
- Source: drugdu
- 61
- December 8, 2025
Breakthrough in Domestic Targeted Radiopharmaceuticals

In the fiercely competitive global race for anti-cancer drug development, targeted radiopharmaceuticals are emerging as a rising star in cancer treatment due to their unique advantages of “precise targeting, high efficiency, and low toxicity.” Recently, Shandong Weizhi Zhike Pharmaceutical ‘s 177Lu-PSMA-VG01 injection received implied clinical approval from the NMPA, marking a crucial step forward for domestically produced targeted radiopharmaceuticals in the treatment of prostate cancer. 01 Technical Analysis Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that plays a crucial role in prostate cancer. Normally, PSMA is expressed at low levels in prostate tissue, but its expression increases dramatically after cell carcinogenesis. It is significantly upregulated in hormone-refractory and metastatic prostate cancer, making it an ideal target for molecular targeted therapy of prostate cancer. Mechanistically, PSMA possesses glutamate carboxypeptidase II activity, hydrolyzing N-acetyl-L-aspartyl-L-glutamate (NAAG), regulating extracellular glutamate levels, influencing neurotransmission and the tumor microenvironment, promoting cancer cell growth ...
- Source: drugdu
- 47
- December 8, 2025
Pfizer launches a series of combined attacks

Recently, the CDE (Center for Drug Evaluation) website showed that Pfizer ‘s marketing application for zavigipan nasal spray has been accepted, intended for the treatment of adult migraines. This drug is the world’s first and only CGRP (calcitonin gene-related peptide) receptor antagonist nasal spray formulation for the treatment of acute migraines. 01 Effective in 15 minutes Zavegepant is a third-generation, high-affinity, selective small-molecule CGRP receptor antagonist. Initially developed by Bristol-Myers Squibb (BMS), the drug was licensed globally by Biohaven Pharmaceutical from BMS in 2016, which was responsible for its subsequent clinical development, manufacturing, and commercialization. In May 2022, Pfizer acquired Biohaven for approximately $11.6 billion , officially adding Zavegepant to its neuroscience pipeline. On March 9, 2023, Zavzpret nasal spray became the first CGRP receptor antagonist nasal spray approved by the U.S. FDA for marketing, becoming the world’s first approved CGRP receptor antagonist nasal spray for the treatment of acute ...
- Source: drugdu
- 57
- December 8, 2025
Minhai Biological, a wholly-owned subsidiary of Kangtai Biological, successfully co-hosted the Vaccine Innovation Forum

China Securities Journal – China Securities Network (Wang Luo) — Recently, the award ceremony for the “19th Pharmaceutical Development Award” was held in Beijing. Liu Jiankai, a Director and Vice President of Kangtai Biological and the Executive Deputy General Manager of Beijing Minhai Biological Technology Co., Ltd. (hereinafter referred to as “Minhai Biological”), was honored with the “Outstanding Achievement Award.” It is understood that the Pharmaceutical Development Award is a medical science award established in 1994, primarily recognizing outstanding scientific and technological talents who have achieved breakthrough innovative results in the medical and health fields. Following the award ceremony, multiple academic exchange sessions were held. Among them, the Vaccine Innovation Forum, themed “Focusing on Frontiers, Interdisciplinary Integration, and Translational Application,” was co-organized by Minhai Biological, a wholly-owned subsidiary of Kangtai Biological. The academic event brought together experts including academicians of the Chinese Academy of Engineering, renowned scholars from universities, specialists ...
- Source: drugdu
- 49
- December 8, 2025
Hinova Pharmaceutical’s new drug, Deuterium Enzalutamide Soft Capsules, is included in the National Medical Insurance Directory for the first time

Report (By reporter Meng Tingting) On the evening of December 7, Haichuang Pharmaceutical Co., Ltd. (hereinafter referred to as “Haichuang Pharmaceutical”) announced that its independently developed Deuterium Enzalutamide Soft Capsules passed national medical insurance negotiations and were included in the National Medical Insurance Drug Catalog for the first time. The catalog will be implemented starting January 1, 2026. Deuterium Enzalutamide Soft Capsules (previously known as: HC-1119 Soft Capsules) are a Class 1 new drug independently developed by Haichuang Pharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a second-generation androgen receptor (AR) inhibitor and received support from the National Science and Technology Major Project for “Major New Drug Innovation and Development”. These capsules are the first domestically produced innovative drug approved in China for mCRPC patients who have progressed after abiraterone acetate and chemotherapy and have not received a novel AR inhibitor. Compared to other endocrine drugs, ...
- Source: drugdu
- 50
- December 8, 2025
Four Drugs Included in the 2025 National Medical Insurance Drug Catalogue

Securities Daily Online News – On the evening of December 7, Betta Pharmaceuticals announced that the company’s products, Icotinib Hydrochloride Tablets, Ensartinib Hydrochloride Capsules, Befotnib Mesylate Capsules, and Vorolanib Tablets, have been included in the National Essential Medical Insurance, Maternity Insurance and Work-Related Injury Insurance Drug Catalogue (2025). https://finance.eastmoney.com/a/202512073584622051.html
- Source: drugdu
- 44
- December 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.